Measuring and improving the timeliness of vancomycin therapeutic drug monitoring and potential patient safety impacts

Background: Timely vancomycin therapeutic drug monitoring (TDM) enables prompt dose adjustments and safe treatment. Local incidents prompted an investigation into the reasons for prolonged reporting times. Objectives: To investigate the variation in reporting times of vancomycin concentrations betwe...

Full description

Saved in:
Bibliographic Details
Main Authors: Belinda Chappell (Author), Benita Suckling (Author), Champika Pattullo (Author)
Format: Book
Published: Elsevier, 2024-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c4e28baf60dd440dab0ad1f27f34bdd1
042 |a dc 
100 1 0 |a Belinda Chappell  |e author 
700 1 0 |a Benita Suckling  |e author 
700 1 0 |a Champika Pattullo  |e author 
245 0 0 |a Measuring and improving the timeliness of vancomycin therapeutic drug monitoring and potential patient safety impacts 
260 |b Elsevier,   |c 2024-03-01T00:00:00Z. 
500 |a 2667-2766 
500 |a 10.1016/j.rcsop.2023.100403 
520 |a Background: Timely vancomycin therapeutic drug monitoring (TDM) enables prompt dose adjustments and safe treatment. Local incidents prompted an investigation into the reasons for prolonged reporting times. Objectives: To investigate the variation in reporting times of vancomycin concentrations between hospitals with and without on-site TDM processing, and patient safety implications. Methods: Vancomycin concentration results for Hospital 1 (off-site monitoring), Hospitals 2 and 3 (both on-site monitoring) from June to December 2021 were retrospectively analysed. Retrospective data collection was repeated for Hospital 1 three months post on-site TDM commencement for comparison. Vancomycin clinical incidents at Hospital 1 were reviewed to identify examples of when delays in reporting of results potentially contributed towards adverse patient outcomes. Results: Hospital 1 had a median reporting time of 11.13 h compared with Hospital 2 and Hospital T3 (1.73 h and 1.70 h respectively). Following the commencement of on-site TDM at Hospital 1, the reporting time reduced to 1.33 h (p < 0.001). Several incidents at Hospital 1 during the period of off-site monitoring involved delays to TDM results. Conclusions: Off-site processing of TDM introduced significant delays in reporting of vancomycin concentrations, which was significantly improved by transitioning to onsite availability of testing. This study also highlights the impact of accurate problem identification in improving patient safety. 
546 |a EN 
690 |a Vancomycin 
690 |a Therapeutic drug monitoring 
690 |a On-site 
690 |a Reporting 
690 |a Systems change 
690 |a Quality improvement 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Exploratory Research in Clinical and Social Pharmacy, Vol 13, Iss , Pp 100403- (2024) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2667276623001841 
787 0 |n https://doaj.org/toc/2667-2766 
856 4 1 |u https://doaj.org/article/c4e28baf60dd440dab0ad1f27f34bdd1  |z Connect to this object online.